164 related articles for article (PubMed ID: 16909426)
21. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
22. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
23. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Andres R; Mayordomo JI; Lara R; Lastra R; Ortega E; Polo E; Lambea J; Isla D; Saenz-Cusi A; Escudero P; Tres A
Clin Breast Cancer; 2005 Jun; 6(2):158-62. PubMed ID: 16001994
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Porta C; Paglino C
BJU Int; 2011 Mar; 107(5):747-748. PubMed ID: 21355979
[No Abstract] [Full Text] [Related]
26. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Santini D; Virzí V; Vincenzi B; Rocci L; Leoni V; Tonini G
Ann Oncol; 2007 Mar; 18(3):576-80. PubMed ID: 17158771
[TBL] [Abstract][Full Text] [Related]
27. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Song HS; Do YR; Chang HM; Ryu MH; Lee KH; Kim YH; Hong DS; Cho JY; Lee KE; Kim SY
Cancer Chemother Pharmacol; 2008 Oct; 62(5):763-8. PubMed ID: 18172648
[TBL] [Abstract][Full Text] [Related]
31. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
32. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
[TBL] [Abstract][Full Text] [Related]
35. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
36. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
37. A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Cho JY; Nam JS; Park MS; Yu JS; Paik YH; Lee SJ; Lee DK; Yoon DS
Yonsei Med J; 2005 Aug; 46(4):526-31. PubMed ID: 16127778
[TBL] [Abstract][Full Text] [Related]
38. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
